Interleukin-4 Receptor alpha Antagonist class drugs

1 result
  • dupixent

    (Dupilumab)
    sanofi-aventis U.S. LLC
    DUPIXENT is indicated for treating moderate-to-severe atopic dermatitis in patients 6 months and older, asthma in patients 6 years and older, chronic rhinosinusitis with nasal polyps in patients 12 and older, eosinophilic esophagitis, prurigo nodularis, inadequate COPD management, chronic spontaneous urticaria over 12, and bullous pemphigoid in adults.